Introduction
Glycogen storage disease type II (GSD II, Pompe's disease) is one of the glycogen storage diseases caused by the deficiency of acid ␣-D-glucosidase (GAA, acid maltase, EC3,2,1,20). The disease is inherited as an autosomal recessive trait. Deficiency of GAA results in impaired glycogen degradation and causes excess glycogen accumulation in lysosome. The clinical phenotypes of GSD II may vary widely from a rapidly progressive infantile form disorder to a slowly progressive adult form myopathy. 1, 2 In Taiwan, the infantile form of GSD II is the most common type. 1, 3 Molecular studies indicate that C1935A transversion in exon 14 with resultant Asp645→Glu substitution in GAA is the most common mutation among Chinese patients with the infantile form of GSD II. 4, 5 This C1935A mutation is due to the founder effect. 3 This disease is relentless and most patients die of cardiac failure and respiratory tract infection in the first year of life. 1, 5 At present, there is no effective treatment for this fatal disease. Though the applicability of enzyme replacement therapy is under investigation, the approach encounters the problems of transient efficiency and high cost. Gene replacement may offer the prospect of lower cost and prolonged treatment effect.
eration of myocytes surrounding the intramuscular injected area as compared with the contralateral muscle of the same birds. Using anti-GAA monoclonal antibody, GAA was demonstrated on the regenerated myocytes by immunohistochemical staining and absent on the contralateral muscle of the same birds. Nevertheless, T lymphocytes infiltration was noted in both the rcAAV-GAA and hepes (medium) injected muscles and more prominent in the rcAAV-GAA-injected site. Functional evaluation demonstrated that wing flapping movement improved with wide flapping in the rAAV-GAA injected side, but not in the counterpart. Unfortunately, these histochemical and functional improvements faded away in 14 days, probably due to destruction of rcAAV by cellmediated immunity of infiltrated T cells. Taken together, the present study suggests that rAAV can enter either human or quail cells and express and effectively reduce the glycogen
Adeno-associated virus (AAV)-based vectors represent a promising gene delivery system. 6 AAV has the ability to transduce in both dividing and non-dividing cells efficiently. 6 In addition, it is a non-pathogenic parvovirus enabling infection of many tissues, including skeletal muscle and brain, to provoke persistent transgene expression. 6 In the absence of a helper virus, AAV integrates its genome into a specific site on chromosome 19 and remains integrated. 7 Recombinant AAV vector construction typically involves removing the rep and cap genes and inserting the transgene of interest between the TR elements. 8 In this study we used the method as described by Xiao et al 9 that used pXX2, pXX6 and target plasmid to produce a higher titer of recombinant rAAV and no host immune response to viral protein. The resultant recombinant AAV was purified by CsCl density gradient. The yield of the rAAV-GAA ranged from 10 10 to 10 11 particles/ml. Among several naturally generated animal models for this disorder, 10 Japanese quails with acid maltase deficiency (AMD) have been well investigated clinically, histologically and biochemically. [11] [12] [13] Clinically, they are very similar to human GSD II and thus appropriate for use in therapeutic experiments.
Several findings suggest that gene transfer may represent an attractive modality to treat GSD II. First, some GAA can normally secrete into systemic circulation and be recaptured by distant cells (such as the cells in liver and muscles) through mannose-6-phosphate receptor. [14] [15] [16] This indicates that gene modification in appropriate depot organs such as liver and muscles may suffice to correct the enzyme deficiency and reverse the diseased state. Second, only minimal levels of the affected enzymes need to be restored for therapeutic correction. 17 In our experience, heterozygotes with as little as 20% of normal enzyme activity are otherwise healthy. Third, the trial of enzyme replacement therapy has been shown to result in clinical improvements in both animal models and patients. 18 Based on these observations, we wished to examine the effects of recombinant AAV encoded human GAA to correct the enzymatic and lysosomal storage defects in AMD Japanese quails.
Results

GAA activity in U293 cells after transient transfection with expression vector
In an attempt to test whether our expression cassette in AAV vector could infect human cells and express GAA, we prepared vector DNA ( Figure 1 ) and transiently transfected 1 g to human U293 cells. GAA activity in the U293 cells and medium was measured 18 h after transfection. The results are shown in Figure 2 . Compared with the pHC-GAA, GAA activity increased five times by pHC-AAV-GAA⌬exon 1 and twice by pcDNA-GAA. GAA activity in the culture medium also increased in proportion using pHC-AAV-GAA⌬exon 1. A similar study was also performed using pHC-AAV-LacZ in each group. There was no difference between any group, either by LacZ staining or ␤-galactosidase activity (data not shown).
Gene Therapy 
Gene Therapy
Secretion of the de novo-synthesized GAA GAA expression in the cytoplasm of cultured AMDdeficient Japanese quail fibroblasts was noted 48 h after transfection with rAAV-GAA (Figure 3a) . Western blot analysis of soup from transduced AMD quail fibroblasts and lysate from AMD quail fibroblasts and GAAdeficient human fibroblasts showed that transduced cells expressed and secreted the 110 kDa precursor and kept processing to the mature 76 to 70 kDa peptide ( Figure  3c ). Only the 110 kDa form could be taken up by the mannose-6-phosphate (M6P) receptors. 19 rAAV-GAA mediated GAA expression in cultured human and Japanese quail fibroblasts U293 cells and fibroblasts obtained from AMD quail or GAA-deficient patients were infected with rAAV-GAA at a dosage of 2 × 10 11 particles/ml. GAA activity in the U293 cells or fibroblasts was measured 48 h after the infection. GAA activity in the U293 cells was 175.87 ± 11.62 nmol/mg/h and reached to 412.85 ± 21.23 nmol/mg/h after rAAV-GAA infection. GAA activity in the untreated GAA-deficient human cultured fibroblast was non-detectable before treatment and reached to 37.76 ± 2.42 nmol/mg/h after rAAV-GAA infection. GAA activity in the untreated normal quail fibroblasts was 4.91 ± 0.72 nmol/mg/h. It was 1.75 nmol/mg/h in the untreated AMD quail fibroblast and slightly increased to 3.76 ± 0.46 nmol/mg/h after rAAV-GAA infection. GAA activity in cultured fibroblast infected with rAAV-LacZ did not increase.
Transient improvement of muscle performance after i.m. rAAV-GAA treatment
We used the flapping test and the flexibility of wings to evaluate functional improvement. In Figure 4a , on the 
injection, the quail could open and flap its right wing (rAAV inj), but the left wing could not move (Hepes inj) (b and c).
Gene Therapy right-hand side, is an AMP quail shown upside down. Its wings are locked and unable to flap. When we hung the quail upside down, they would get nervous and try to flap their wings. However, the AMD quail could not flap given their weak wings. Figure 4b and c show that on the 4th day after i.m. treatment of the right wing with rAAV-GAA, the injected wing was able to flap in a flip test (Figure 4a and b) . The contra-lateral wing injected with medium was still unable to move and remained in the locked position (Figure 4b and c). The other way to evaluate the wing function is the flexibility of wings. In normal quails, the wings are very flexible and can flap freely, but the wings of the AMD quail were rigid. On the 4th day after i.m. rAAV-GAA treatment, we also found the flexibility of the right wing had improved. Unfortunately, this functional improvement disappeared on day 14.
rAAV-GAA mediated in vivo GAA expression in muscle by i.m. administration
In an attempt to correct the enzyme deficiency in the AMD quails, animals were i.m. injected with 0.1 ml of 2 × 10 11 particles/ml rAAV-GAA at 10 different sites of unilateral deep pectoral muscle. The counter-lateral muscle was i.m. injected with 0.1 ml medium (hepes) at 10 different sites to serve as control. Group I animals were killed 4 days and group II animals 14 days after injection. Sampled muscles were stained with H&E, PAS ( Figure  5 ), and in situ with acid ␣-D-glucosidase ( Figure 6 ). In the group I animals, 4 days after injection, the muscle fibers around the rAAV-GAA injection site were normalized in morphology. The vacuoles and glycogenosomes in the cytoplasm of muscle fibers were absent, the size of the myocyte decreased (PAS stain, Figure 5a ) with positive staining of acid ␣-D-glucosidase (Figure 6a ) surrounding the area of i.m. rAAV-GAA injection, marked by Indian ink. Unfortunately, scattered lymphocytes infiltration was also noted (Figure 5c ). To determine which arm of the host immune response was responsible for our rAAV vectors, in situ immunochemical staining was carried out using human anti-CD3, CD4, CD8, CD19 monoclonal antibodies. Only anti-CD3 activity demonstrated immunochemical stain (Figure 5c ). Also, reappearance of glycogenosomes on day 14 (group II) after i.m. rAAV-GAA injection with absence of mononuclear lymphocytes infiltration was observed. The immunohistological stain of acid ␣-glucosidase on the injected site muscles showed negative staining on day 14.
rAAV-GAA mediated in vivo GAA expression in liver by i.v. administration
In an attempt to evaluate the liver production of GAA in the AMD quails, animals were injected i.v. via jugular vein with a single dose of 0.6 ml (6 × 10 10 rAAV-GAA particles). Groups I, II and III animals were killed at 4, 28, and 52 h after injection, respectively. Group IV animals were controls and received an i.v. injection of medium (hepes) only. Sampled livers were stained with H&E, PAS and in situ with acid ␣-D-glucosidase. Acid ␣-D-glucosidase activity was measured. Very low levels of GAA activity (4.32 ± 0.21 nmol/mg protein/h) were detected in the liver tissue of untreated animals. In contrast, 4 h after i.v. injection of rAAV-GAA, high levels of GAA activity (38.83 ± 1.11 nmol/mg protein/h) were detected in the liver tissue. This level was nine times 
rAAV-GAA treatment. The glycogen in the myocyte is degraded, the size of the myocyte is decreased, the color is lighter after i.m. rAAV-GAA injection at 4 days (a), but there is no such improvement in the Hepes injection muscle. Large amounts of glycogen storage within myocytes with heavy PAS positive stain were noted (b), and mononuclear cells infiltration in the rAAV injection muscle at 4th day was noted (c), the infiltration mononuclear cells in rAAV injection muscle at the 4th day after injection is CD3 + cells (the brown spot in the cells) (e). (The area of injection was marked by Indian ink, PAS stain, ×600).
higher than that in controls. Quantative GAA activity was also detectable in the plasma. Unfortunately, GAA activity declined 24 and 48 h after i.v. injection of rAAV-GAA, to the levels of 26.89 ± 1.23 nmol/mg/h and 19.28 ± 1.14 nmol/mg/h, respectively.
In immunohistochemical studies, the time course of GAA expression seemed to correspond to the GAA 
Discussion
Currently, several animal models of GSD II have been evaluated, including AMD-deficient Japanese quails and GAA knockout (KO) mice. 21 However, the onset of disease in KO mice is slow and the neurological manifestations, 21 are different from those of human GSD II. The onset of disease in AMD Japanese quails appears at the age of 4 weeks without abnormal neurological manifestation. [11] [12] [13] Their functional improvement is also easy to evaluate. 18 These characteristics encouraged us to use AMD Japanese quail for evaluation of this disease through a gene therapeutic approach.
Adeno-associated virus has a large host range, and AAV type 2 vectors seem able to enter chicken cells.
22
Figure 7 Immunohistochemistry staining after i.v. rAAV-GAA injection. It is proved that human GAA is expressed in the liver after 4 h (a), 24 h (b), and 48 h (c) of i.v. injection, but it is has a tendency to rapidly decrease, also in the liver of untreated AMD quail (d) and normal quail (e) (×400).
The most important feature of AAV is the requirement for coinfection with an unrelated virus, such as Ad, to provide essential helper functions for a productive life cycle. To produce rAAV, the traditional procedure is to use Ad infection to provide Ad helper functions. However, there are numerous problems: it will generate Ad particles or Ad proteins that will induce unwanted immune response, and the competition between AAV and Ad for critical viral gene functions affects the final yield of vectors. To avoid all the problems of Ad contamination, we used a vector production system from the North Carolina group that is completely free of Ad. This sytem uses a plasmid construct which contains a miniAd genome capable of propagating rAAV in the presence of AAV Rep and Cap genes. This construct is missing Gene Therapy some of the early and most of the late Ad genes and is incapable of producing infectious Ad. In addition we use an AAV packaging plasmid pXX2 which utilizes translational control of AAV Rep genes. Combination of these two plasmids increases rAAV vector yields several-fold. Enzyme replacement therapy in AMD Japanese quails showed that only a high dose is effective. 18 In other words, highly efficient gene transduction is necessary for therapeutic efficacy. The study of Chen et al found a repressor in exon of GAA gene. 23 Therefore, we constructed an exon 1 (⌬1) deleted rAAV containing CMV promoter, AAVITR region, AAV poly A tail and ampicillin resistance gene (pHC-AAV-GAA⌬exon 1). Our transient transfection study using pcDNA-GAA⌬1 demonstrated that the amount of acid GAA increased five-fold
Figure 8 Liver histological staining after i.v. rAAV-GAA injection. Using a serial study, we can see that glycogensome accumulation is greatly ameliorated after rAAV i.v. injection at 4 h (a) and 24 h (b) and even 48 h (c) as after rAAV i.v. injection compared with mock-treated AMD quail liver (d). The normal quail liver (e) is used for control (PAS stain, ×400).
as compared with controls and three-fold with pcDNA-GAA. This pHC-AAV-GAA⌬exon 1 plasmid may be appropriate for GAA expression.
As shown by H&E, PAS and immunohistological staining, histochemical assay and functional studies, transient functional improvement and reduction of glycogen accumulation were observed in the rAAV-GAA i.m. injected site of AMD quail pectoral muscle, but not in the contralateral site muscle injected with medium (hepes). Hence, rAAV-GAA can enter the muscle cells to express the precursor form of GAA and secrete GAA from these cells. The surrounding cells may also express the mannose-6-phosphate receptor, uptake the secreted GAA, and then digest glycogen. The observation of almost complete elimination of glycogen in the muscle cells surrounding the i.m. injected site (Figure 5a ) and in the liver after i.v. injection (Figure 8b ) supports this assumption.
The study by Xiao et al 9 reported that pXX6 can escape some of the early and most of the later adenovirus genes and can avoid host immune response. This is the reason we chose pXX6 as our study plasmid. In this study immune response was noted. It might have been induced by pXX2 and pXX6 plasmid. Immune response may also be due to the use of human GAA in this approach. The homology between human and quail genomic DNA of GAA is only 63%. From the preliminary results in the clinical trial of recombinant GAA treatment by Chen et al in the deficiency of GAA protein GSD II patients, there was anti-GAA Ab development with loss of clinical efficacy. Therefore, host immune response events tended to abolish observed efficacy. In the immune response of infiltrating lymphocytes we could only demonstrate that some of them were CD3 + T cells. Because we were only able to use anti-human T cell subsets and B cells monoclonal Ab to perform immunohistochemical study, there was no crossreaction between human and quail lymphocytes.
After in vitro transduction of rAAV-GAA in AMD quail fibroblasts, the GAA activity only increased around 20%. This suggests that some barriers exist on the surface of quail cells and only 20% of our AAV-2 were able to enter quail cells. To provide evidence that quail liver is actually transduced by rAAV-GAA, a genomic DNA PCR study was performed using the liver tissue of two dead quails at 52 h after GAA vector intravenous injection. We could get either AAV-2 of CMV promoter DNA (data not shown). Thus, another reason for the transient expression of our rAAV-GAA may be related to the CMV promoter. Some studies have shown that the promoter in rAAV may influence the expression and persistency of carrying genes. 27 CMV promoter is stronger than native promoter in quail cells. The internal regulation may turn off the function of CMV promoter. Other factors may also be involved in extinguishing expression, including loss of vector and promoter shut off. Currently, several strategies are deemed to be effective in minimizing these problems. For example, promoters such as EF-1 (elongation factor promoter) or liver specific promoter, and immunosuppressents can be used to improve the transduction and gene expression efficiency of rAAV vectors.
Our results raise two potential issues. One is that host immune response events tended to abolish the observed efficacy. The other is that the low rAAV transduction rate in quail cells tended to minimize the secretion of GAA. Quail acid maltase (AM) cDNAs have been cloned. Quails have two species of AM encoded by different genes. The more predominant species of quail AM (GAAI) is less homologous to human GAA and its mRNA is missing in the muscle, liver, heart and brain of AMD quail. The mRNA of the other species of quail AM (GAA II) is observed in both normal and AMD quail muscles. The internal regulation of quail AM may also turn off the function of CMV promoter in our rAAV-GAA.
In summary, we have shown that the i.m. administration of an rAAV-GAA can transiently mediate functional and histological improvement and expression of GAA in the pectoral muscles of AMD quails. Intravenous administration of a rAAV-GAA can transiently mediate histological improvement and expression of GAA in the liver of AMD quails.
Materials and methods
Construction and preparation of recombinant AAV
Briefly, the full-length acid ␣-glucosidase cDNA was excised with EcoRI from the pACTER-1, a gift from A Reuser (Erasmus University, Rotterdam, The Netherlands) 25 and ligated into the multicloning site of the mammalian expression vector pcDNA 3 (Invitrogen, Carlsbad, CA, USA) to give a 9-kb plasmid, pcDNA3-Gene Therapy GAA. A 547-bp fragment, starting at 18 bp 5' of the ATG start codon and ending at 529 bp into the coding sequence of acid ␣-glucosidase, was prepared by PCR amplification using the primers GAA224 (+) (5'-TCC-AGG-CCA-TCT-CCA-ACC-AT-3') and GAA751 (Ϫ) (5'-TCC-AGG-CCA-TCA-TCA-TCA-CG-3') (20) and cloned into pTOPO plasmid (Invitrogen). The resultant plasmid, pTOPO 224-P2, contained a HindIII site 5' relative to the ATG start codon and a SacII site 320 bp into the coding sequence of acid ␣-glucosidase. pcDNA-GAA⌬1, containing the 5'-truncated version of the acid ␣-glucosidase cDNA, was then constructed by replacing the HindIIISacII fragment of pcDNA-GAA with the HindIII-SacII fragment of pTOPO224-P2. pcDNA-GAA⌬1 then was treated with NruI and BbsI and ligated to pHC-AAV plasmid containing AAV-ITR region and poly A to give a resultant plasmid, pPHC-AAV-GAA⌬1 (Figure 1) .
Plasmids, cells and viruses
An rAAV vector plasmid, pHC-AAV/CMV-LacZ used in all packaging experiments was kindly provided by Dr Hsieh. This vector plasmid contains the AAV IRs flanking the cytomegalovirus (CMV) early transcription promoter.
Human 293 (Ad-5 transformed embryonic kidney epithelial cells) cells were grown in Dulbecco's modified Eagle medium (Gibco) supplemented with 10% fetal bovine serum and antibiotics. Cells were maintained in monolayer cultures in a 5% CO 2 atmosphere at 37°C.
Preparation of pXX2 and pXX6
The AAV packaging plasmids were constructed based on plasmid pAAV/Ad. Construction of packaging plasmid pACG2 was reported previously. 9 Packaging plasmid pXX2 was constructed from pACG2 by inserting a promoter p5 element downstream of the capsid gene. The Ad helper plasmid pxx6 was constructed by cloning the large ClaI-SalI fragment of pXX5 into ClaI-SalI sites of the high-copy-number plasmid pBluescript KS (+) (Stratagene, La Jolla, CA, USA). pXX6 further lost an 8.5-kb fragment containing the Ad terminal protein gene, as well as the Ad major late promoter.
Packaging, rAAV vector production and titration
Briefly, 1 to 2 h before transfection, each plate of human 293 cells (70 to 80% confluent), 15 cm in diameter, was fed with 20 ml of fresh Dulbecco's modified Eagle medium (Gibco) containing 10% fetal bovine serum (HyClone) without antibiotics. A total of 50 g of plasmid DNA was dissolved in 2.5 ml of 0.25 M CaCl 2 , immediately mixed with 2.5 ml of HEPES-buffered saline (50 mM HEPES, 280 mM NaCl, 1.5 mM Na 2 HPO 4 (pH 7.12)) and added to the cells. Eight to 12 h after transfection, the medium was replaced with fresh Dulbecco modified Eagle medium (Gibco) containing 10% fetal bovine serum and antibiotics. To optimize the experiments, the vector-tohelper-plasmid ratios of pHC-AAV-GAA⌬1:pxx2:pxx6 were 1:1:3 (10 g/10 g/30 g/per plate), respectively. When pXX2 and pXX6 were used to supply the helper functions, the cytopathic effect was less intense and the cells were harvested 48 h after transfection unless specified otherwise. After low-speed centrifugation on a tabletop centrifuge, the cell pellets were resuspended in 1 ml of 100 mM NaCl-10 mM Tris-HCl (pH 8.5) and subjected to four cycles of freeze-thaw and removal of cell debris. The rAAV virus lysate was heated at 56°C for 30 min to inactivate any adenovirus that may have been produced and stored at Ϫ20°C until use. Large-scale rAAV preparation and CsCl 2 density gradient purification were carried out by a previously reported method. 8, 9 For large-scale vector packaging, 20 × 15 cm plates, each containing 5 × 10 6 293 cells, were transfected with pHC-AAV-GAA̅1, pXX2 and pXX6 in a ratio of 1:1:3 using the calcium phosphate transfection procedure. Forty-eight to 60 h later, the cultures were harvested, the cells were pelleted by low-speed centrifugation, and the pellets were frozen and thawed four times and sonicated as described above. CsCl 2 was added to the lysate to a final concentration of 1.3 g/ml, as determined by the refractive index. The suspension was centrifuged in a Sorvall AH-629 rotor for 20 h at 25 000 r.p.m. The visible vector-containing band was removed from the gradient, and its density was determined by measuring the refractive index. The CsCl 2 centrifugation step was repeated, and the resultant vector preparation was dialyzed against four changes of PBS and stored at -80°C. The titer of resultant vector was titrated by an AAV titration ELISA kit (Progen Biotechnik, Heidelberg, Germany).
AAV titration AAV titration ELISA kit was used (Progen, ImmunoDiganostika, Heidelberg, Germany). The assay was based on a sandwich ELISA technique. A monoclonal antibody specific for a conformational epitope on assembled AAV capsids was coated on to microtiter strips and used to capture AAV particles from the specimen. Then a biotinconjugated monoclonal antibody to AAV and streptavidin peroxidase conjugate was applied on the specimen. Addition of substrate solution resulted in a color reaction which was proportional to specifically bound virus particles.
Measurement of GAA activity in cells, muscles and liver and immunofluoresence detection of GAA
Immunofluorescence
staining: The intracellular expression of recombinant GAA in deficient fibroblasts and myoblasts was analyzed by immunofluorescence staining. Cells were washed with PBS buffer and fixed on a glass slide by incubating with 2% formaldehyde in PBS at room temperature for 45 min. Before each incubation with antibodies, cells were incubated with 10% goat serum in PBS for 1 h at room temperature, and washed with PBS. Cells were incubated first for 1 h at room temperature with the first primary antibody, and then incubated overnight at 4°C with the second antibody. Primary antibody was monoclonal Ab against human GAA prepared in our laboratory. 24 Secondary antibody was conjugated with FITC.
␣-D-Glucosidase assay:
The activity of acid ␣-D-glucosidase was assayed by using 4-methylumbelliferyl-␣-Dglucopyranoside as substrate with the following modifications. Twenty-microliter cell suspensions or homogenated muscle tissues were incubated with 50 l of 1 mM 4-methylumbelliferyl-␣-D-glucopyranoside in citrate phosphate buffers (pH 4 and 6) for 2 h. 1 ml of 400 mM glycine-NaOH buffer, pH 10.5 was added before the fluorescence test. Fluorescence was determined in a Hitachi or an Aminco-Bowmen spectrofluorometer with an excitation wavelength of 365 nm and an emission wavelength 
Animals
AMD quails (strain RWN) and normal quails (strain PNN) were obtained from the Nippon Institute for Biological Science Farm, Kobuchizawa, Yamahashi, Japan. Sex identification and clinical assessment for wing dysfunction were performed at 3 weeks after hatching. The animals were cared for in compliance with the law and related standards for animal welfare. 18 AMD quails are able to reproduce and maintain as a homozygous breeding population. In them, the age of onset of clinical symptoms varies among individual birds. At 4 weeks of age, all 12 male AMD quails represented the clinical symptoms of AMD as evidenced by inability to rise on their own in a flip test and the wings were in a locked position when held upside down by the legs. Two normal male birds of the same age, that were able to rise on their own in a flip test and to flap their wings when held upside down, were used as controls.
Quail fibroblasts and infection with rAAV
Fibroblasts were obtained from the skin of 9-day AMD and normal embryos. 22 The cells were dissociated with trypsin and cultured in Dulbecco's modified Eagle's medium containing 8% fetal bovine serum and 2% chicken serum, penicillin (50 U/ml), streptomycin (50 g/ml), and iron-bound chick transferrin (20 g/ml). Cultured fibroblasts (10 6 cells/infection) were infected with rcAAV-GAA (10 11 particles/ml). Forty-eight hours after the infection, cells were harvested, washed three times with PBS, and enzyme activities in the cell homogenate and the media were assayed with 4-methylumbelliferyl ␣-D-glucopyranoside (4-MUG) as described above. Each assay was done in duplicate.
In vivo gene transfer and sampling
In vivo experiment 1: i.m. administration: Six AMD quails were included and treated from 4 weeks of age. The clinical manifestation features of AMD were confirmed before treatment. A dosage of 0.1 ml of 2 × 10 11 particles/ml rAAV-GAA, combined with Indian ink as a marker, was injected using a 27-gauge needle with a total dose of 1 ml into 10 different sites of unilateral deep pectoral muscle of an AMD quail. The contralateral muscle was similarly injected with 10 doses of 0.1 ml medium (HEPES) with Indian ink as control. Each bird was evaluated for signs of clinical improvement by the flip test and locked wings when held upside down. Muscle biopsies were taken from injection sites as marked by Indian ink on days 4 and 14. Muscle tissues were examined histologically for morphology and glycogen distribution, and GAA expression. The same tissues from two normal birds were also studied.
In vivo experiment 2: i.v. administration:
Six birds received intravenous bolus injection of 0.6 ml of 6 × 10 10 particles rAAV-GAA from the jugular vein. Two birds each time were killed at 4, 28 and 52 hours, respectively. Another two AMD quails received bolus i.v. injection of 0.6 ml medium (HEPES) from the jugalar vein and were killed at 4 h to serve as control.
Histological, histochemical and immunochemical studies (liver, muscles)
To specifically preserve glycogen, tissues were fixed for 12 h with UFIX and then embedded in paraffin. Glycogen was visualized by staining the tissue sections with periodic acid-Schiff (PAS) and hematoxylin, and confirmed by loss of stainable PAS-positive granules after diastase digestion. 18, 21, 22 The serial sections were also stained with hematoxylin and eosin for histopathological analysis. 18 
